Analyst Price Targets — NKTR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 21, 2026 12:50 pm | — | Wedbush | $95.00 | $101.64 | TheFly | Nektar price target raised to $95 from $70 at Wedbush |
| April 20, 2026 2:33 pm | — | H.C. Wainwright | $185.00 | $106.75 | TheFly | Nektar price target raised to $185 from $165 at H.C. Wainwright |
| March 13, 2026 4:39 pm | Jay Olson | Oppenheimer | $140.00 | $73.27 | StreetInsider | Nektar Therapeutics (NKTR) PT Raised to $140 at Oppenheimer |
| February 10, 2026 5:17 pm | — | BTIG | $151.00 | $52.00 | TheFly | Nektar price target raised to $151 from $118 at BTIG |
| February 10, 2026 2:16 pm | — | H.C. Wainwright | $165.00 | $52.62 | TheFly | Nektar price target raised to $165 from $135 at H.C. Wainwright |
| January 26, 2026 1:56 pm | Yasmeen Rahimi | Piper Sandler | $105.00 | $36.35 | StreetInsider | Piper Sandler on Nektar Therapeutics (NKTR): 'We See a Substantial Opportunity Into These De-Risked Data' |
| December 16, 2025 5:48 pm | — | H.C. Wainwright | $135.00 | $51.17 | TheFly | Nektar price target raised to $135 from $120 at H.C. Wainwright |
| December 16, 2025 4:08 pm | Jay Olson | Oppenheimer | $115.00 | $50.43 | TheFly | Nektar price target raised to $115 from $98 at Oppenheimer |
| November 24, 2025 10:35 am | Roger Song | Jefferies | $121.00 | $54.28 | StreetInsider | Nektar Therapeutics (NKTR) PT Raised to $121 at Jefferies |
| September 18, 2025 7:55 pm | Roger Song | Jefferies | $99.00 | $58.74 | TheFly | Nektar price target raised to $99 from $69 at Jefferies |
Latest News for NKTR
Bragar Eagel and Squire, P. C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Nektar (NKTR) To Contact Him Directly To Discuss Their Options If you purchased or acquired Nektar securities between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Bragar Eagel and Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Nektar (NKTR) To Contact Him Directly To Discuss Their Options
Critical Information: $4.14 Per-Share Loss Quantifies Alleged Investor Damages Critical Information: $4.14 Per-Share Loss Quantifies Alleged Investor Damages
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the “Class Period”), of the important May 5, 2026 lead plaintiff deadline.
BENSALEM, Pa., April 27, 2026 /PRNewswire/ -- The Law Offices of Howard G.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NKTR.
U.S. House Trading
No House trades found for NKTR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.